Bausch & Lomb (TSX:BLCO) Debt-to-Equity : 0.67 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Debt-to-Equity?

Bausch & Lomb's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$40 Mil. Bausch & Lomb's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$6,080 Mil. Bausch & Lomb's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$9,190 Mil. Bausch & Lomb's debt to equity for the quarter that ended in Dec. 2023 was 0.67.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bausch & Lomb's Debt-to-Equity or its related term are showing as below:

TSX:BLCO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.35 Max: 0.67
Current: 0.67

During the past 6 years, the highest Debt-to-Equity Ratio of Bausch & Lomb was 0.67. The lowest was 0.00. And the median was 0.35.

TSX:BLCO's Debt-to-Equity is ranked worse than
81.04% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs TSX:BLCO: 0.67

Bausch & Lomb Debt-to-Equity Historical Data

The historical data trend for Bausch & Lomb's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Debt-to-Equity Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.35

0.67

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.35	0.36	0.38	0.66	0.67

Competitive Comparison of Bausch & Lomb's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Debt-to-Equity falls into.

Bausch & Lomb Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bausch & Lomb's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.248	+	6080.131)	/	9189.96
	=	0.67

Bausch & Lomb's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.248	+	6080.131)	/	9189.96
	=	0.67

Bausch & Lomb (TSX:BLCO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bausch & Lomb Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.